| Literature DB >> 22017682 |
Randall T Peterson1, Calum A Macrae.
Abstract
As the current paradigms of drug discovery evolve, it has become clear that a more comprehensive understanding of the interactions between small molecules and organismal biology will be vital. The zebrafish is emerging as a complement to existing in vitro technologies and established preclinical in vivo models that can be scaled for high-throughput. In this review, we highlight the current status of zebrafish toxicology studies, identify potential future niches for the model in the drug development pipeline, and define the hurdles that must be overcome as zebrafish technologies are refined for systematic toxicology.Entities:
Mesh:
Substances:
Year: 2011 PMID: 22017682 DOI: 10.1146/annurev-pharmtox-010611-134751
Source DB: PubMed Journal: Annu Rev Pharmacol Toxicol ISSN: 0362-1642 Impact factor: 13.820